GILD 10-K Analysis: The $636M Pricing Gap Wall Street Hasn't Quantified

Gilead Sciences, the $29 billion HIV-treatment franchise that generates 71% of revenue from a single therapeutic area, reported a 1,673% net income surge in its FY 2025 10-K — from $480 million to $8.5 billion. Wall Street celebrated. But buried in the filing's geographic revenue tables is a number no analyst has quantified: $636 million.

That's how much Biktarvy's U.S. revenue fell short of what it would have earned at international growth rates — the first hard-dollar measurement of the IRA's pricing impact, derived not from models but from Gilead's own data. Biktarvy, which alone represents 48.7% of total company revenue, grew just 5.6% domestically while international sales expanded 11.5%. The divergence isn't explained by market dynamics or competitive shifts; the filing itself attributes U.S. pricing pressure to the Medicare Part D redesign under the Inflation Reduction Act.

But the pricing gap is only one layer of what the 10-K reveals. The headline earnings "recovery" is approximately 90% accounting noise from prior-year IPR&D charges that didn't repeat. The reported EPS of $6.78 includes a $450 million one-time tax settlement, making normalized earnings $6.42 — which shifts the P/E from 17.9x to 19.1x. And while three regulatory pricing threats converge on Gilead's core franchise, the adjusted operating business underneath genuinely improved 20% year-over-year. The tension between accelerating pricing headwinds and real operational improvement is the investment question this filing forces.

The $636 Million Silent Tax

Every earnings call, every analyst report discusses the IRA's impact on pharmaceutical pricing in qualitative terms — "headwinds," "uncertainty," "potential pressure." Gilead's 10-K provides the data to move from speculation to measurement.

Biktarvy, the company's dominant HIV treatment generating $14.3 billion in FY 2025 revenue, grew at starkly different rates by geography. U.S. revenue increased from $10,855 million to $11,467 million — a gain of $612 million, or 5.6%. Europe grew from $1,509 million to $1,676 million (+11.1%). Rest of World expanded from $1,060 million to $1,190 million (+12.3%). The international markets, not subject to the IRA's Medicare Part D redesign, grew at roughly double the U.S. rate.

The arithmetic is straightforward: if Biktarvy's U.S. revenue had grown at the 11.5% composite international rate, the U.S. business would have added $1,248 million rather than $612 million. The $636 million gap is the IRA's quantified annual cost — derived entirely from filing data, no model assumptions required.

But the pricing pressure extends well beyond Part D. The filing discloses two additional threats converging on the same franchise. First, direct executive action:

"In July 2025, the President sent letters to Gilead and other pharmaceutical manufacturers outlining the steps the President believes pharmaceutical manufacturers must take to bring down the prices of prescription drugs in the U.S. to match the MFN price offered internationally."

Most-favored-nation pricing would be qualitatively more severe than Part D negotiation. If Biktarvy's U.S. price were forced to European levels, the revenue impact would dwarf the current $636 million gap.

Second, the IRA's direct price negotiation mechanism is expanding — from 10 drugs in 2026 to 15 in 2027 and 2028, and 20 annually thereafter. And third, the OBBB Act's expiration of enhanced ACA premium subsidies at the end of 2025 threatens not just pricing but patient volume — a risk Gilead has never previously faced in its HIV franchise.

"requires the Department of Health and Human Services to 'negotiate' Medicare prices for certain drugs (starting with 10 drugs in 2026, adding 15 drugs in 2027 and 2028, and adding 20 drugs in 2029 and subsequent years), which could also affect the Medicaid rebate obligations and the ceiling prices charged to covered entities under Section 340B."

The gross-to-net picture reinforces this. Gilead's rebates and chargebacks totaled $15.5 billion in FY 2025 — meaning 34.8% of estimated gross product sales of $44.4 billion never reached the revenue line. The rebate liability balance grew from $4,493 million to $4,646 million, consistent with escalating pricing concessions. Gilead's Biktarvy U.S. revenue grew only 5.6% in FY 2025 while international revenue grew 11.5%, a ~$636 million pricing gap caused by the IRA's Medicare Part D redesign — the first hard-dollar measurement of regulatory pricing erosion from the company's own filing data.

Behind the Headline Numbers

A 1,673% net income surge — from $480 million to $8.5 billion — is the kind of number that stops a screener cold. But the 10-K reveals this headline is almost entirely an artifact of FY 2024's denominator, not FY 2025's numerator.

FY 2024 net income was depressed by $8.0 billion in acquired IPR&D charges: $3.8 billion from the CymaBay write-off and $4.2 billion from the Immunomedics NSCLC indication impairment. These are non-cash, non-operating charges that crushed FY 2024's net income to $480 million. When those charges simply didn't repeat in FY 2025, net income mechanically recovered to $8.5 billion. Roughly 90% of the "earnings explosion" reflects the prior year's artificial depression, not current-year improvement.

The earnings quality issues compound. Reported EPS of $6.78 includes a $450 million one-time tax benefit from a Q4 settlement:

"In October 2025, we reached a settlement with a tax authority related to a prior year legal entity restructuring. As a result, we recognized approximately $450 million of income tax benefit and a corresponding $530 million reduction in our unrecognized tax benefits in the quarter ending December 31, 2025."

Strip out the settlement and the effective tax rate rises from 13.1% to 17.7% — reflecting Gilead's operational rate under its Irish subsidiary structure, not a one-time windfall. Normalized EPS of $6.42 yields a P/E of 19.1x, not the widely cited 17.9x. Additionally, $400 million in non-recurring constrained IP revenue recognition inflated the revenue line, making underlying revenue growth approximately 1.0% rather than the reported 2.4%.

But the 10-K also contains a counterweight that makes the picture genuinely complicated. Stripping out all IPR&D charges and restructuring costs, adjusted operating income grew from $9,850 million to $11,774 million — a 20% improvement. SG&A declined 5.2% while R&D spending was essentially flat. Operating cash flow declined 7.5% to $10.0 billion, but the filing reveals a critical one-time drag:

"Net cash provided by operating activities decreased in 2025, compared to 2024, primarily due to higher inventory build-up and higher income tax payments, as well as unfavorable timing of accounts receivable collections. In 2025, we paid the final $1.3 billion federal income tax payment for transition tax on the mandatory deemed repatriation."

That $1.3 billion won't repeat, implying underlying OCF of approximately $11.3 billion — a 4.5% improvement over FY 2024. Gilead's reported $6.78 EPS includes a $450 million one-time tax settlement that inflated earnings by $0.36/share, making the normalized P/E 19.1x rather than the widely cited 17.9x — a difference that shifts the stock from "cheap value pharma" to "fairly priced with pricing headwinds."

But beneath the earnings quality question sits a second concern: whether the balance sheet can bear both IRA pricing pressure and aggressive capital allocation simultaneously. Gilead spent $9.1 billion in FY 2025 — dividends, buybacks, debt repayment, and acquired IPR&D — against $10.0 billion in operating cash flow. That left $920 million in residual cash before the $7.8 billion Arcellx acquisition arrives. The earnings are improving, but the capital being deployed against them is accelerating faster.

The $30 Billion Oncology Question

Gilead's balance sheet tells a story of serial acquisition with diminishing returns. The intangibles footnote reveals $29.6 billion in gross acquired intangible assets — a number that dwarfs most comparable pharma acquisitions and reflects a decade-long bet on diversification away from antiviral dependence.

The return on that capital has been poor. The three largest acquired assets are Trodelvy at $11.73 billion (from the $21 billion Immunomedics deal), sofosbuvir at $10.72 billion (the original Pharmasset blockbuster), and Yescarta at $7.11 billion (Kite Pharma's CAR-T platform). Combined, these generated $4.2 billion in FY 2025 revenue against $2.4 billion in annual intangible amortization.

The impairment pattern is especially troubling. Gilead has written down acquired IPR&D in three consecutive fiscal years: $188 million in 2023, $8.0 billion in 2024 (CymaBay + Immunomedics NSCLC), and $1.6 billion in 2025. The bulevirtide story is emblematic — impaired twice in a single year as competitive data eroded the asset's estimated fair value:

"In the second quarter of 2025 and again in the fourth quarter of 2025, additional data became available indicating a more competitive market for bulevirtide where it is not yet approved. Based on our evaluation of the data... we performed impairment tests and determined that the revised estimated fair value of the bulevirtide IPR&D intangible asset was below its carrying amount."

Against this track record, the $7.8 billion Arcellx acquisition — targeting next-generation CAR-T for multiple myeloma — represents either a pattern break or the next chapter of capital destruction. The case for pattern-break: Arcellx targets myeloma (a different market than the failed NSCLC and HBV bets), and Yescarta's established manufacturing infrastructure reduces execution risk. The case for continuation: Yescarta itself declined 5% in FY 2025 against Carvykti competition, cell therapy overall fell 7%, and the balance sheet is absorbing $7.8 billion in new acquisition cost.

Post-Arcellx, estimated total debt rises to approximately $30 billion, pushing the debt-to-equity ratio from 1.10x to approximately 1.32x. Meanwhile, capital allocation in FY 2025 was aggressive: $4.0 billion in dividends, $1.9 billion in buybacks (up 67% year-over-year), and $1.8 billion in debt repayment consumed $7.7 billion — leaving only $920 million of residual OCF before the Arcellx cash needs arrive. Gilead has impaired $4.8 billion in acquired oncology assets over two consecutive years while Trodelvy, its largest intangible at $11.73 billion, generates only $1.4 billion in annual revenue — a return rate that questions the acquisition discipline behind the $7.8 billion Arcellx deal.

The PrEP Catalyst and the Coverage Cliff

If the IRA pricing gap and acquisition track record represent Gilead's bear case, the PrEP franchise is its most compelling bull catalyst — and the FY 2025 10-K provides unusually direct evidence.

Descovy, the leading daily oral PrEP product, grew 31% to $2,758 million. The geographic decomposition is striking: U.S. revenue surged from $1,902 million to $2,559 million — a $657 million addition — while international revenue actually declined by $12 million. The entire growth story is U.S. PrEP adoption. This isn't a global demand wave; it's a domestic public health expansion that validates the market mechanism Yeztugo is designed to capture.

Yeztugo (lenacapavir for PrEP), approved in December 2025, addresses the single largest barrier to PrEP adherence: daily dosing. Twice-yearly injection versus daily pill is a meaningful behavioral improvement in a prevention population. The CDC recommendation, PEPFAR partnership for 2 million people over three years, and a $1 billion inventory build in FY 2025 all signal launch conviction.

But the same filing that validates the PrEP growth thesis also contains its complication:

"the OBBB Act did not extend the availability of enhanced premium subsidies, which subsidize patient premiums for Affordable Care Act health insurance exchange plans and expired at the end of 2025. If these subsidies are not reinstated, it is possible that patient enrollment in ACA exchange plans could substantially decrease."

This creates an unusual race condition. The PrEP market is expanding at roughly 35% annually based on Descovy's trajectory, and Yeztugo's superior dosing convenience should accelerate adoption. But the OBBB Act simultaneously threatens the insurance coverage that makes PrEP economically accessible. Medicaid work requirements and tighter eligibility taking effect in 2027 compound the risk.

The investment question is whether Yeztugo's adoption curve outpaces the contraction of the insured PrEP-eligible population. Peak revenue estimates of $3-4 billion assume continued coverage expansion; if coverage contracts before Yeztugo reaches scale, $2-2.5 billion may be the realistic ceiling. Gilead's Descovy grew 31% in FY 2025 with 100% of that growth coming from U.S. PrEP prescriptions ($657 million addition), validating the market expansion that Yeztugo's twice-yearly dosing targets — but the OBBB Act's expiration of ACA premium subsidies threatens to shrink the addressable patient population.

What to Watch

At $122.74, Gilead trades at 17.9x reported earnings — a number that suggests value in a sector where Amgen commands 22.8x and Abbott 33.6x. But normalized for the $450 million tax settlement, the P/E is 19.1x. At normalized free cash flow of approximately $10.6 billion (adjusting for the non-recurring $1.3 billion transition tax), the EV/FCF is 16.0x. The market is pricing a business that grows FCF at 3-4% in perpetuity.

GILD's lower P/E (17.9x vs AMGN 22.8x) looks cheap until you account for growth — GILD +2.4% vs AMGN +10.0%. The FCF yield advantage (6.19% vs peers) is real but reflects mature cash generation, not expansion upside. The value case depends entirely on pricing stabilization and PrEP launch success.

The filing supports that growth rate — but also complicates it. Three metrics will determine whether the multiple holds or compresses:

1. Biktarvy U.S. vs international growth gap. In FY 2025, this gap was approximately 6 percentage points (5.6% vs 11.5%). If it narrows below 3 points in Q1-Q2 2026, the pricing erosion is stabilizing. If it widens past 8 points, the $636 million annual cost is accelerating — and the market's growth assumption may be too generous.

2. Yeztugo quarterly revenue trajectory. First full quarter of sales (Q1 2026) will establish the launch curve. Above $200 million validates a $3-4 billion peak scenario; below $50 million suggests adoption friction exceeds PrEP market expansion momentum.

3. Post-Arcellx leverage. Debt-to-equity will move from 1.10x to approximately 1.32x. If management finances the deal with more cash than expected (keeping D/E below 1.2x), the balance sheet story improves. If D/E exceeds 1.4x, the buyback program ($1.9 billion in FY 2025) almost certainly pauses and dividend coverage tightens.

At $122.74, the market implies 3-4% perpetual FCF growth. The filing supports this if operational improvement (+20% adjusted OpInc) and PrEP expansion (Descovy +31%) outpace the three-headed pricing threat. The Biktarvy geographic gap is the thesis thermometer. At 5.6% vs 11.5%, it signals ~$636 million per year in pricing erosion. In Q1-Q2 2026, if this gap narrows below 3 points, pricing stabilization strengthens and the normalized EV/FCF of 16.0x is reasonable. If it widens past 8 points, pricing pressure is accelerating — the stock has less margin of safety, the denominator changes, and Gilead is no longer cheap.

Frequently Asked Questions

How much is the IRA Part D redesign already costing Gilead?

Approximately $636 million per year in unrealized U.S. Biktarvy revenue, based on geographic revenue decomposition from the FY 2025 10-K. Biktarvy U.S. revenue grew +5.6% while international revenue grew +11.5%. If U.S. growth had matched international rates, Biktarvy's U.S. revenue would have been approximately $636M higher. This represents roughly 2.2% of total company revenue or 6% of normalized free cash flow. The figure captures only the Part D redesign effect; additional impacts from future direct Medicare price negotiations (starting 2026-2027) and MFN executive action could increase this significantly.

Is Gilead's 1,673% net income growth real?

No. Approximately 90% of the net income increase is accounting noise, not operational improvement. FY 2024 net income of $480M was depressed by $8.0B in IPR&D charges ($3.8B CymaBay acquisition + $4.2B Immunomedics NSCLC impairment) that did not repeat in FY 2025. On an adjusted basis stripping IPR&D and restructuring, operating income grew approximately 20% YoY — from $9.85B to $11.77B. The underlying business genuinely improved, but the headline number vastly overstates the magnitude.

What is Gilead's real earnings per share?

Reported EPS was $6.78 for FY 2025. However, this includes a $450M one-time tax benefit from a Q4 2025 settlement with a tax authority. Normalizing for this settlement yields an effective tax rate of 17.7% (vs 13.1% reported) and normalized EPS of approximately $6.42. Additionally, $400M in non-recurring constrained IP revenue recognition inflated revenue. The business's sustainable earnings power is closer to $6.10-6.20/share, implying a P/E of ~19.8-20.1x rather than the reported 17.9x.

How does Gilead's product concentration compare to peers?

Gilead's Biktarvy represents 48.7% of total revenue — nearly identical to Merck's Keytruda at 48.7% of pharmaceutical revenue. Both face extreme single-product concentration risk. However, the nature differs: Keytruda faces a 2028 patent cliff, while Biktarvy faces gradual pricing erosion from regulatory action with no near-term generic competition. Amgen provides contrast with no single product exceeding ~12% of revenue, though AMGN still faces $11B in legacy products at biosimilar risk.

Can Yeztugo really become a $3-4B product?

The filing provides indirect but strong validation. Descovy — the current leading PrEP product — grew 31% in FY 2025, with 100% of that growth coming from U.S. PrEP prescriptions ($657M addition). Yeztugo addresses the #1 barrier to PrEP adherence (twice-yearly injection vs daily pill), received CDC recommendation, and has a PEPFAR partnership. However, the OBBB Act's expiration of ACA premium subsidies could limit the addressable PrEP population. Peak sales of $3-4B assume continued coverage expansion; if coverage contracts, $2-2.5B may be more realistic.

Is Gilead's dividend safe after the Arcellx acquisition?

Mathematically tight but likely sustainable. FY 2025 dividends were $4.0B on $10.0B OCF. Post-Arcellx ($7.8B closing Q2 2026), estimated debt rises to ~$29-30B, pushing D/E to ~1.3x. But the $1.3B non-recurring transition tax payment won't repeat in FY 2026 (improving underlying OCF to ~$11.3B), the $2.5B undrawn revolver provides emergency liquidity, and Gilead pre-positioned $3.5B in notes in November 2024. The dividend appears safe but buybacks ($1.9B in FY25) will likely be curtailed post-Arcellx.

What are the three pricing threats converging on Gilead?

The FY 2025 10-K discloses three escalating pricing pressures: (1) IRA Medicare Part D redesign (active since 2025, already costing ~$636M/year in Biktarvy pricing gap), with direct price negotiations expanding from 10 drugs in 2026 to 20/year by 2029; (2) MFN executive action — a July 2025 presidential letter demanding U.S. prices match the lowest international price, followed by a government pricing agreement with undisclosed terms; (3) OBBB Act coverage erosion — ACA premium subsidies expired end-2025 and Medicaid eligibility tightens in 2027, threatening HIV patient volume, not just pricing.

How does Gilead's oncology acquisition track record look?

Poor by the numbers. The intangibles footnote reveals $29.6B in gross acquired intangible assets. The three largest — Trodelvy ($11.73B), sofosbuvir ($10.72B), Yescarta ($7.11B) — generated combined FY 2025 revenue of $4.2B. Annual intangible amortization is $2.4B. Additionally, $4.8B in IPR&D has been impaired over 2024-2025. Trodelvy, acquired via Immunomedics for ~$21B, recovers only 11.9% of its gross carrying value per year in revenue.

Why does Gilead's tax rate matter for this analysis?

Because a 4.6 percentage point ETR difference ($6.78 vs $6.42 EPS) changes the P/E from 17.9x to 19.1x — shifting Gilead from "cheap value pharma" to "fairly priced with pricing headwinds." The 13.1% reported effective tax rate was driven by a Q4 2025 settlement producing $450M in one-time benefit. Gilead's operational ETR of 17.7% reflects its Irish subsidiary structure. Every forward P/E estimate using $6.78 overstates earnings power by ~5.3%.

What would make the bull case for Gilead at current prices?

Three things need to go right: (1) Yeztugo must reach $2B+ in annual revenue within 3 years, leveraging the PrEP expansion validated by Descovy's 31% growth; (2) the adjusted operating business must maintain its 20% improvement trajectory via cost discipline and revenue mix shift; (3) the IRA/MFN pricing gap must stabilize near $636M/year rather than doubling. At $122.74, normalized EV/FCF of 16.0x is reasonable for 3-4% FCF growth. The operating improvement is real, the PrEP catalyst is real, and the balance sheet is manageable if OCF recovers as the transition tax rolls off.

What single metric should investors watch going forward?

The Biktarvy U.S.-vs-international growth rate gap. In FY 2025, this gap was ~6 percentage points (5.6% vs 11.5%). If it narrows to less than 3 points in Q1-Q2 2026, pricing erosion is stabilizing and the bull case strengthens. If it widens to more than 8 points, pricing pressure is accelerating faster than volume can compensate. This is the single most direct, filing-verifiable measurement of IRA's financial impact on Gilead.

How does Gilead's FCF generation compare to peers?

Gilead leads among mature pharma peers on FCF yield (6.19% vs MRK 4.69%, AMGN 4.60%, ABT 3.39%) and FCF margin (32.1% vs AMGN 22.0%, MRK 19.0%, ABT 16.7%). This reflects Gilead's asset-light model: only $563M in CapEx on $29.4B revenue (1.9% capex intensity). The HIV franchise is essentially a royalty stream — high-margin, low-capital-intensity, generating $9.5B in FCF. The risk is not generation quality but sustainability under pricing erosion.

Methodology

Data Sources

This analysis is based on Gilead Sciences' FY 2025 Annual Report (10-K), filed with the SEC on February 24, 2026, accessed via the MetricDuck filing text API with chunk-level section granularity. Standardized financial metrics for Gilead and peer companies (AMGN, MRK, ABT) were calculated using the MetricDuck analysis pipeline. Peer comparison data covers FY 2025 reported results from each company's most recent 10-K filing.

Derived calculations — including the $636M geographic pricing gap, normalized ETR and EPS, adjusted operating income, and acquisition ROI metrics — use explicit formulas documented in the research process. All derived numbers can be reconstructed from the filing's geographic revenue tables, tax footnotes, intangible asset disclosures, and liquidity discussion.

Limitations

• Geographic decomposition assumption. The $636M IRA pricing shortfall assumes Biktarvy's international growth rate (11.5%) is a clean proxy for demand-only growth. In practice, international markets have their own pricing dynamics (government tenders, reference pricing). The true IRA-only impact may be somewhat higher or lower.
• Yeztugo revenue estimates are indirect. No Yeztugo revenue exists yet (FDA approved December 2025). The PrEP market expansion thesis relies on Descovy as a proxy for market demand. Actual Yeztugo uptake may differ due to pricing, insurance coverage, and patient preference factors.
• Arcellx financing structure unknown. The $7.8B acquisition is announced but the financing mix (cash vs debt) is not disclosed. Post-Arcellx leverage calculations assume various scenarios but the actual structure may differ.
• MFN agreement terms undisclosed. The filing confirms a government pricing agreement exists but does not disclose its terms. The financial impact of MFN pricing is therefore qualitative rather than quantified.
• OBBB Act implementation uncertainty. Medicaid work requirements and eligibility changes effective 2027 may be modified, delayed, or expanded by legislative action. The volume risk to HIV demand is directionally certain but magnitude is unknowable from the filing.

Disclaimer:

This analysis is for informational purposes only and does not constitute investment advice. The author does not hold positions in GILD, MRK, AMGN, ABT, or ABBV. Past performance and current metrics do not guarantee future results. All data is derived from public SEC filings and may contain errors or omissions from the automated extraction process.